Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles
Authors:
- 4 October 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 31 (11) , 1213-1218
Abstract
C-Met inhibitor JNJ38877605 has proven curative as an antitumor agent, while its clinical study was terminated due to renal toxicity. It was reported that the renal toxicity was caused by the poor solubility of its aldehyde oxidase (AO) metabolites. Therefore, blocking AO oxidation of JNJ38877605 might diminish the toxic metabolites and overcome the renal toxicity. Compound 3, the AO metabolic site deuterated JNJ38877605, was then synthesized as the target molecule. In vitro monkey liver S9 fraction incubation of 3 manifested that the renal toxic metabolite M2-2 significantly reduced, which connoted that this deuteration has partly blocked AO oxidation. After po. nasal gavage to cynomolgus monkeys, compound 3 revealed decreased AO metabolites M2-2 and M3-2 in the plasma, as well as 1.88-fold AUC and 1.56-fold Cmax compared with JNJ38877605, indicating that deuterium replacement significantly blocked AO metabolism in vivo. Besides, metabolic pro-files of 3 were investigated by analysis of the plasma and the urine of the po. administrated cynomolgus monkeys. Moreo-ver, after oral administration to the EBC-1 tumor-bearing nude mice, compound 3 exhibited a better antitumor efficacy than JNJ38877605. In conclusion, deuteration on the AO metabolic site of JNJ38877605 improved its AO metabolism, oral exposure, as well as in vivo antitumor efficacy.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2018ZX09711002-004-013, 2018ZX09711002-011-016)
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2018324)
- Science and Technology Commission of Shanghai Municipality (17YF1423300)
- National Natural Science Foundation of China (21702220, 81573271)
This publication has 27 references indexed in Scilit:
- Medicinal chemistry approaches to avoid aldehyde oxidase metabolismBioorganic & Medicinal Chemistry Letters, 2012
- Systematic Structure Modifications of Imidazo[1,2-a]pyrimidine to Reduce Metabolism Mediated by Aldehyde Oxidase (AO)Journal of Medicinal Chemistry, 2011
- Case report of extensive metabolism by aldehyde oxidase in humans: Pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humansXenobiotica, 2011
- Aurora Kinase Inhibitors Based on the Imidazo[1,2-a]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral Absorption and ExposureJournal of Medicinal Chemistry, 2010
- MET signalling: principles and functions in development, organ regeneration and cancerNature Reviews Molecular Cell Biology, 2010
- In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitorThe Pharmacogenomics Journal, 2010
- Targeting the c-MET signaling pathway for cancer therapyExpert Opinion on Investigational Drugs, 2008
- Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applicationsExpert Opinion on Therapeutic Patents, 2007
- A deuterium isotope effect on the inhibition of gastric secretion by N,N-dimethyl-N'-[2-(diisopropylamino)ethyl]-N'-(4,6-dimethyl-2-pyridyl)urea. Synthesis of metabolitesJournal of Medicinal Chemistry, 1983
- Deuterium isotope effects in the in vivo metabolism of cotinineJournal of Medicinal Chemistry, 1974